Our Commitment to an Equitable, Sustainable Future

BeiGene is pleased to release its first global Environmental, Social and Governance (ESG) report.

By defining a set of ESG goals and formalizing a strategy to achieve them, our company can demonstrate its commitment to improving its performance and contributions to society. As we continue to grow as a global organization of 6,000-plus colleagues working across five continents, we have an even greater opportunity – and responsibility – to effect change.

We have a duty to the millions of patients battling cancer today and an obligation to continue to advance novel and affordable therapies capable of reaching everyone who needs them. Progressing this research and facilitating greater access to life-saving therapies is critical to creating a more equitable world.

But we must remember that how we achieve this vision is equally important. We remain committed to not only delivering innovative and affordable medicines but also to upholding the highest standards of ethics and integrity, operational excellence and environmental stewardship.

Our ESG framework reflects our determination to be a positive and transformational force for the world, our industry, and the communities in which we live and work. This inaugural global ESG report outlines our approach to managing these ESG issues, which we believe are material for BeiGene’s future, from clinical trial excellence to product safety and quality to sustainability.

ESG performance results will be shared each year in subsequent reports.

Access the full report here.

2021 ESG Report